Partnering in Japan: The Athersys : Healios Story
Sponsored by Nikon Cell Innovation Co.
Organized by the ISCT Business Models and Investment Subcommittee of the Commercialization Committee
Wednesday, December 12 /Thursday, December 13 (Japan)
14:30 PST, 17:30 EST, 07:30 JST (Dec 13)
CLICK HERE TO REGISTER BY DECEMBER 11
- Bill Milligan, SVP, Steminent Biotherapeutics Inc., Co-Chair; ISCT Business Models and Investor Subcommittee
- Gil van Bokkelen, PhD, Chairman and CEO, Athersys, United States
- Hardy Kagimoto, MD, Chairman and CEO, Healios, Japan
- Kim Raineri, MBA, Vice President of Operations, Nikon Cell Innovation Co, Japan
About the Webinar:
Favorable regulatory changes enacted at PMDA in November 2014 introduced potential for conditional market approval of CGT / RM therapeutic candidates after Phase II clinical development and led to increased interest for partnering in Japan. As a result, ISCT and FIRM formed a partnership in October 2017 to facilitate creating a better understanding of the opportunity these changes present for the respective ISCT and FIRM communities of organizations.
The first session for the ISCT Japan Webinar Series in December 2017 focused on clarifying the new, PMDA regulatory changes to support CGT clinical development in Japan. PCT/Hitachi sponsored and provided perspective in this webinar which can be accessed on the ISCT website.
This second session in the ISCT Japan Series is focused on the actual partnering experience, how to partner, the value of partnering, and key learnings from the active Athersys : Healios Japan partnership. This webinar will provide insights and learning from Athersys (US) and Healios (Japan) leadership as well as provide the manufacturing perspective for Japan partnerships from Nikon (Japan). Athersys, Healios and Nikon demonstrate that biotechs, chemical companies, CMOs, and other organizations beyond Big Japanese Pharma are active in seeking and developing Japanese CGT / RM partnerships.
Registration for this Webinar has been sponsored by Nikon Cell Innovation Co.